Pheochromocytoma (Oncology) - Drugs In Development, 2021

August 2021 | 179 pages | ID: P48050F37756EN
Global Markets Direct

Abstracts

Pheochromocytoma (Oncology) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma - Drugs In Development, 2021, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape.Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL) and neurofibromatosis 1 (NF1).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pheochromocytoma - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Pheochromocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Pheochromocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 11, 3 and 1 respectively.

Pheochromocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Pheochromocytoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Pheochromocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Pheochromocytoma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Pheochromocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Pheochromocytoma (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Pheochromocytoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Pheochromocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Pheochromocytoma - Overview
Pheochromocytoma - Therapeutics Development
Pheochromocytoma - Therapeutics Assessment
Pheochromocytoma - Companies Involved in Therapeutics Development
Pheochromocytoma - Drug Profiles
Pheochromocytoma - Dormant Projects
Pheochromocytoma - Discontinued Products
Pheochromocytoma - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Pheochromocytoma, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pheochromocytoma - Pipeline by Advanced Accelerator Applications SA, 2021
Pheochromocytoma - Pipeline by AstraZeneca Plc, 2021
Pheochromocytoma - Pipeline by Chimerix Inc, 2021
Pheochromocytoma - Pipeline by Enterome Bioscience SA, 2021
Pheochromocytoma - Pipeline by Exelixis Inc, 2021
Pheochromocytoma - Pipeline by Fujifilm Holdings Corp, 2021
Pheochromocytoma - Pipeline by Gibson Oncology LLC, 2021
Pheochromocytoma - Pipeline by Ipsen SA, 2021
Pheochromocytoma - Pipeline by Jubilant DraxImage Inc, 2021
Pheochromocytoma - Pipeline by Lixte Biotechnology Holdings Inc, 2021
Pheochromocytoma - Pipeline by Merck & Co Inc, 2021
Pheochromocytoma - Pipeline by Pfizer Inc, 2021
Pheochromocytoma - Pipeline by Tarveda Therapeutics Inc, 2021
Pheochromocytoma - Pipeline by Vyriad Inc, 2021
Pheochromocytoma - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Pheochromocytoma, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021